» Articles » PMID: 33149755

The Mechanisms of Sijunzi Decoction in the Treatment of Chronic Gastritis Revealed by Network Pharmacology

Overview
Date 2020 Nov 5
PMID 33149755
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic gastritis is characterized by inflammation in the gastric mucosa with a vicious circle in inflammatory cells and inflammatory mediators. Stomach adenocarcinoma would occur in the metaplastic gastric mucosa of chronic gastritis. Sijunzi decoction is a famous classical formula for the treatment of chronic gastritis. Although previous studies revealed some functions of Sijunzi decoction in treating chronic gastritis, the underlying mechanisms have not been illustrated clearly. In this study, we used network pharmacology to investigate the mechanism of Sijunzi decoction in treating chronic gastritis. Firstly, online datasets TCMSP, SWISS, and DisGeNET were used to investigate the functional mechanism of Sijunzi decoction against chronic gastritis and 18 genes were identified as targets of Sijunzi decoction in chronic gastritis. These 18 genes can be categorized into immunologically related genes and cancer-related genes. GO analysis showed that the 18 target genes were mainly enriched in angiogenesis, nitric oxide biosynthetic process, ERK1 and ERK2 cascade, cellular response to drug, and MAPK cascade. So, Sijunzi decoction alleviated chronic gastritis by inhibiting the local inflammatory response. Furthermore, we also investigated the impact of Sijunzi decoction on the peripheral blood leukocytes with our own RNA sequencing (RNA-seq) data of 11 chronic superficial gastritis patients. 102 differentially expressed genes (DEGs) were identified by comparing RNA-seq data of chronic superficial gastritis patients with healthy control groups. After performing a functional analysis on 102 DEGs and Sijunzi decoction potential targets and taking the intersection of these pathways, we found that platelet activation, angiogenesis, and pathways in cancer were candidate target pathways regulated by Sijunzi decoction. Thus, Sijunzi decoction also alleviates chronic gastritis by suppressing inflammatory response of peripheral blood leukocytes. Our results showed that Sijunzi decoction can ameliorate the local gastric inflammation and inflammations in peripheral blood leukocytes and might also reduce the incidence of stomach cancer in chronic gastritis.

Citing Articles

Molecular targets and mechanisms of Sijunzi decoction in the treatment of Parkinson's disease: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation.

Jiang Y, Wu W, Xie L, Zhou Y, Yang K, Wu D Front Pharmacol. 2024; 15:1487474.

PMID: 39660000 PMC: 11629541. DOI: 10.3389/fphar.2024.1487474.


Application of network pharmacology in traditional Chinese medicine for the treatment of digestive system diseases.

Zheng S, Liang Y, Xue T, Wang W, Li S, Zhang P Front Pharmacol. 2024; 15:1412997.

PMID: 39086391 PMC: 11289720. DOI: 10.3389/fphar.2024.1412997.


Sijunzi decoction alleviates inflammation and intestinal epithelial barrier damage and modulates the gut microbiota in ulcerative colitis mice.

Li H, Pu X, Lin Y, Yu X, Li J, Bo L Front Pharmacol. 2024; 15:1360972.

PMID: 38650625 PMC: 11033371. DOI: 10.3389/fphar.2024.1360972.


Exploring the Potential Molecular Mechanism of Sijunzi Decoction in the Treatment of Non-Segmental Vitiligo Based on Network Pharmacology and Molecular Docking.

Du Z, Wang H, Gao Y, Zheng S, Kou X, Sun G Clin Cosmet Investig Dermatol. 2023; 16:821-836.

PMID: 37033783 PMC: 10075956. DOI: 10.2147/CCID.S403732.


A study of the therapeutic mechanism of Jakyakgamcho-Tang about functional dyspepsia through network pharmacology research.

Choi W, Choi N, Park E, Kim B Int J Med Sci. 2022; 19(13):1824-1834.

PMID: 36438925 PMC: 9682510. DOI: 10.7150/ijms.77451.


References
1.
Tian G, Wu C, Li J, Liang B, Zhang F, Fan X . Network pharmacology based investigation into the effect and mechanism of Modified Sijunzi Decoction against the subtypes of chronic atrophic gastritis. Pharmacol Res. 2019; 144:158-166. DOI: 10.1016/j.phrs.2019.04.012. View

2.
Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H . The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 2014; 465(1):25-33. DOI: 10.1007/s00428-014-1588-4. View

3.
Mezouar S, Frere C, Darbousset R, Mege D, Crescence L, Dignat-George F . Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res. 2016; 139:65-76. DOI: 10.1016/j.thromres.2016.01.006. View

4.
May A, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M . Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation. 2002; 106(16):2111-7. DOI: 10.1161/01.cir.0000033597.45947.0f. View

5.
Farinati F, Piciocchi M, Lavezzo E, Bortolami M, Cardin R . Oxidative stress and inducible nitric oxide synthase induction in carcinogenesis. Dig Dis. 2010; 28(4-5):579-84. DOI: 10.1159/000320052. View